50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
'A Gold Storm Is Coming' (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
'A Gold Storm Is Coming' (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
'A Gold Storm Is Coming' (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
'A Gold Storm Is Coming' (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
'A Gold Storm Is Coming' (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
'A Gold Storm Is Coming' (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
'A Gold Storm Is Coming' (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
'A Gold Storm Is Coming' (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
NASDAQ:AFMD

Affimed - AFMD Stock Forecast, Price & News

$2.00
-0.03 (-1.48%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.95
$2.08
50-Day Range
$2.00
$3.32
52-Week Range
$1.93
$7.35
Volume
1.19 million shs
Average Volume
1.26 million shs
Market Capitalization
$246.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Affimed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
400.0% Upside
$10.00 Price Target
Short Interest
Healthy
3.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.64mentions of Affimed in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.67) to ($0.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

303rd out of 1,080 stocks

Pharmaceutical Preparations Industry

125th out of 535 stocks

AFMD stock logo

About Affimed (NASDAQ:AFMD) Stock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Stock News Headlines

Affimed (NASDAQ:AFMD) Receives $10.00 Consensus PT from Analysts
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
Recap: Affimed Q2 Earnings - Benzinga
Preview: Affimed's Earnings
See More Headlines
Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Company Calendar

Last Earnings
8/11/2022
Today
9/24/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
197
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-68,060,000.00
Net Margins
-232.11%
Pretax Margin
-223.00%

Debt

Sales & Book Value

Annual Sales
$47.76 million
Book Value
$1.30 per share

Miscellaneous

Free Float
N/A
Market Cap
$246.84 million
Optionable
Optionable
Beta
2.32

Key Executives

  • Dr. Adi Hoess (Age 61)
    CEO, MD & Member of Management Board
    Comp: $786.03k
  • Mr. Angus W. Smith (Age 40)
    CFO & Member of Management Board
    Comp: $566.18k
  • Dr. Wolfgang Fischer (Age 58)
    MD, COO & Member of Management Board
    Comp: $619.39k
  • Ms. Denise Mueller (Age 53)
    Chief Bus. Officer & Member of Management Board
    Comp: $540.08k
  • Dr. Andreas Harstrick M.D. (Age 61)
    Chief Medical Officer & Member of Management Board
    Comp: $513.98k
  • Dr. Arndt J. G. Schottelius M.D. (Age 56)
    Ph.D., Chief Scientific Officer & Member of Management Board
    Comp: $621.39k
  • Prof. Melvyn Little
    Founder & Consultant
  • Mr. Michael Wolf (Age 55)
    Head of Fin. & Admin.
  • Mr. Alexander Fudukidis
    Head of Investor Relations
  • Dr. Uwe Reusch
    Head of Cell Culture













AFMD Stock - Frequently Asked Questions

Should I buy or sell Affimed stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings
or view top-rated stocks.

What is Affimed's stock price forecast for 2022?

7 Wall Street analysts have issued 1-year target prices for Affimed's shares. Their AFMD share price forecasts range from $7.00 to $12.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for AFMD
or view top-rated stocks among Wall Street analysts.

How have AFMD shares performed in 2022?

Affimed's stock was trading at $5.52 at the beginning of the year. Since then, AFMD shares have decreased by 63.8% and is now trading at $2.00.
View the best growth stocks for 2022 here
.

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our AFMD earnings forecast
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) released its quarterly earnings data on Thursday, August, 11th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The biopharmaceutical company earned $7.78 million during the quarter, compared to analysts' expectations of $8.12 million. Affimed had a negative trailing twelve-month return on equity of 54.94% and a negative net margin of 232.11%.

What other stocks do shareholders of Affimed own?
What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by many different retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (5.23%), Pictet Asset Management SA (3.88%), Woodline Partners LP (2.03%), State Street Corp (1.82%), Bain Capital Public Equity Management II LLC (1.03%) and Northern Trust Corp (0.80%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $2.00.

How much money does Affimed make?

Affimed (NASDAQ:AFMD) has a market capitalization of $246.84 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does Affimed have?

The company employs 197 workers across the globe.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.